Table 1:
Summary of demographic variables (excluding SES proxies) and common comorbidities in the final study populations for each cohort, post-missing data imputation.
| Norway (N=1672) |
Russia (N=1155) |
UK (N=1064) |
Overall (N=3891) |
|
|---|---|---|---|---|
| AGE | ||||
| Mean (3D) | 51.8 (13.6) | 59.6 (14.4) | 59.0 (12.6) | 56.1 (14.1) |
| Median [Min, Max] | 52.0 [17.0, 96.0] | 59.0 [20.0, 100] | 59.0 [19.0, 91.0] | 56.0 [17.0, 100] |
| SEX | ||||
| Female | 1139 (68.1%) | 688 (59.6%) | 434 (40.8%) | 2261 (58.1%) |
| Male | 533 (31.9%) | 467 (40.4%) | 630 (59.2%) | 1630 (41.9%) |
| ASTHMA | ||||
| ABSENT | 1305 (78.1%) | 1076 (93.2%) | 818 (76.9%) | 3199 (82.2%) |
| PRESENT | 367 (21.9%) | 79 (6.8%) | 246 (23.1%) | 692 (17.8%) |
| CHRONIC CARDIAC DISEASE (NOT HYPERTENSION) | ||||
| ABSENT | 1547 (92.5%) | 877 (75.9%) | 952 (89.5%) | 3376 (86.8%) |
| PRESENT | 125 (7.5%) | 278 (24.1%) | 112 (10.5%) | 515 (13.2%) |
| CHRONIC HAEMATOLOGICAL DISEASE | ||||
| ABSENT | 1642 (98.2%) | 1137 (98.4%) | 1032 (97.0%) | 3811 (97.9%) |
| PRESENT | 30 (1.8%) | 18 (1.6%) | 32 (3.0%) | 80 (2.1%) |
| CHRONIC KIDNEY DISEASE | ||||
| ABSENT | 1635 (97.8%) | 1081 (93.6%) | 1004 (94.4%) | 3720 (95.6%) |
| PRESENT | 37 (2.2%) | 74 (6.4%) | 60 (5.6%) | 171 (4.4%) |
| CHRONIC NEUROLOGICAL DISORDER | ||||
| ABSENT | 1556 (93.1%) | 1087 (94.1%) | 1013 (95.2%) | 3656 (94.0%) |
| PRESENT | 116 (6.9%) | 68 (5.9%) | 51 (4.8%) | 235 (6.0%) |
| CHRONIC PULMONARY DISEASE (NOT ASTHMA) | ||||
| ABSENT | 1602 (95.8%) | 1037 (89.8%) | 875 (82.2%) | 3514 (90.3%) |
| PRESENT | 70 (4.2%) | 118 (10.2%) | 189 (17.8%) | 377 (9.7%) |
| DIABETES MELLITUS (TYPE 2) | ||||
| ABSENT | 1542 (92.2%) | 942 (81.6%) | 846 (79.5%) | 3330 (85.6%) |
| PRESENT | 130 (7.8%) | 213 (18.4%) | 218 (20.5%) | 561 (14.4%) |
| DIABETES MELLITUS (TYPE NOT SPECIFIED) | ||||
| ABSENT | 1646 (98.4%) | 934 (80.9%) | 828 (77.8%) | 3408 (87.6%) |
| PRESENT | 26 (1.6%) | 221 (19.1%) | 236 (22.2%) | 483 (12.4%) |
| HYPERTENSION | ||||
| ABSENT | 1322 (79.1%) | 475 (41.1%) | 685 (64.4%) | 2482 (63.8%) |
| PRESENT | 350 (20.9%) | 680 (58.9%) | 379 (35.6%) | 1409 (36.2%) |
| MALIGNANT NEOPLASM | ||||
| ABSENT | 1626 (97.2%) | 1099 (95.2%) | 1034 (97.2%) | 3759 (96.6%) |
| PRESENT | 46 (2.8%) | 56 (4.8%) | 30 (2.8%) | 132 (3.4%) |
| OBESITY | ||||
| ABSENT | 1638 (98.0%) | 878 (76.0%) | 1006 (94.5%) | 3522 (90.5%) |
| PRESENT | 34 (2.0%) | 277 (24.0%) | 58 (5.5%) | 369 (9.5%) |
| RHEUMATOLOGICAL DISORDER | ||||
| ABSENT | 1356 (81.1%) | 1090 (94.4%) | 884 (83.1%) | 3330 (85.6%) |
| PRESENT | 316 (18.9%) | 65 (5.6%) | 180 (16.9%) | 561 (14.4%) |
| SMOKING | ||||
| ABSENT | 1627 (97.3%) | 1011 (87.5%) | 958 (90.0%) | 3596 (92.4%) |
| PRESENT | 45 (2.7%) | 144 (12.5%) | 106 (10.0%) | 295 (7.6%) |
| Long COVID QALDs | ||||
| Mean (SD) | 322 (59.2) | 338 (48.9) | 269 (94.3) | 312 (73.4) |